The investigation demonstrated that ML210, a known glutathione peroxidase 4 (GPX4)-targeting compound, exhibits dual pharmacological activity by antagonizing ABCB1 function and reversing chemoresistance in CRC models with ABCB1-driven MDR. Here, GPX4 is linked to colorectal carcinoma.